WO2011153243A3 - Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac - Google Patents
Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac Download PDFInfo
- Publication number
- WO2011153243A3 WO2011153243A3 PCT/US2011/038765 US2011038765W WO2011153243A3 WO 2011153243 A3 WO2011153243 A3 WO 2011153243A3 US 2011038765 W US2011038765 W US 2011038765W WO 2011153243 A3 WO2011153243 A3 WO 2011153243A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gastric cancer
- treating gastric
- angiogenesis therapy
- angiogenesis
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des méthodes et des compositions comprenant des anticorps anti-VGEF destinés à être utilisés dans le traitement du cancer de l'estomac.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35079810P | 2010-06-02 | 2010-06-02 | |
US61/350,798 | 2010-06-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011153243A2 WO2011153243A2 (fr) | 2011-12-08 |
WO2011153243A3 true WO2011153243A3 (fr) | 2012-01-19 |
Family
ID=44627141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/038765 WO2011153243A2 (fr) | 2010-06-02 | 2011-06-01 | Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011153243A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104292330B (zh) * | 2013-03-08 | 2017-07-14 | 上海赛伦生物技术股份有限公司 | 一种稳定性高的人源抗vegf抗体及其应用 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
TWI639430B (zh) * | 2016-08-27 | 2018-11-01 | 中國醫藥大學 | 醫藥組合物用於製備治療胃癌藥物的用途 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20090099344A1 (en) * | 2003-07-28 | 2009-04-16 | Fahrner Robert L | Reducing protein a leaching during protein a affinity chromatography |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
CA2129663C (fr) | 1992-02-06 | 2005-07-05 | James S. Huston | Proteine fixatrice biosynthetique pour marqueur du cancer |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
HU221343B1 (en) | 1992-10-28 | 2002-09-28 | Genentech Inc | Use of anti-vegf antibodies for the treatment of cancer |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
DE69842174D1 (de) | 1997-04-07 | 2011-04-21 | Genentech Inc | Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
WO1999022764A1 (fr) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Compositions renfermant des glycoformes de glycoproteine et methodes afferentes |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
CA2838062C (fr) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2526085A1 (fr) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Traitement au moyen d'anticorps anti-vegf |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (fr) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anticorps anti-vegf |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
-
2011
- 2011-06-01 WO PCT/US2011/038765 patent/WO2011153243A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20090099344A1 (en) * | 2003-07-28 | 2009-04-16 | Fahrner Robert L | Reducing protein a leaching during protein a affinity chromatography |
Non-Patent Citations (8)
Title |
---|
"793 Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 3, no. 2, 1 October 2005 (2005-10-01), pages 226, XP005132907, ISSN: 1359-6349 * |
B. F. EL-RAYES ET AL: "A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers", ANNALS OF ONCOLOGY, vol. 21, no. 10, 23 March 2010 (2010-03-23), pages 1999 - 2004, XP055012999, ISSN: 0923-7534, DOI: 10.1093/annonc/mdq065 * |
CATALANO V ET AL: "Gastric cancer", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 71, no. 2, 1 August 2009 (2009-08-01), pages 127 - 164, XP026251198, ISSN: 1040-8428, [retrieved on 20090220], DOI: 10.1016/J.CRITREVONC.2009.01.004 * |
JAVLE MILIND ET AL: "Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 3, no. 1, 23 March 2010 (2010-03-23), pages 11, XP021083337, ISSN: 1756-8722, DOI: 10.1186/1756-8722-3-11 * |
KELSEN D ET AL: "Analysis of survival with modified docetaxel, cisplatin, fluorouracil, and bevacizumab in patients with metastatic gastroesophageal adenocarcinoma: Results of a phase II clinical trial", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 27, 1 January 2009 (2009-01-01), pages 4512, XP009154355, ISSN: 0732-183X * |
MORABITO A ET AL: "Systemic treatment of gastric cancer", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 70, no. 3, 1 June 2009 (2009-06-01), pages 216 - 234, XP026104335, ISSN: 1040-8428, [retrieved on 20081001], DOI: 10.1016/J.CRITREVONC.2008.08.005 * |
NINOMIYA S ET AL: "Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 154, no. 2, 15 June 2009 (2009-06-15), pages 196 - 202, XP026151213, ISSN: 0022-4804, [retrieved on 20080916], DOI: 10.1016/J.JSS.2008.08.017 * |
SHAH MANISH A ET AL: "Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 NOV 2006 LNKD- PUBMED:17114652, vol. 24, no. 33, 20 November 2006 (2006-11-20), pages 5201 - 5206, XP009154389, ISSN: 1527-7755 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011153243A2 (fr) | 2011-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
WO2014031487A8 (fr) | Inhibiteurs bivalents de protéines iap et méthodes thérapeutiques les utilisant | |
EP2714081A4 (fr) | Méthodes, compositions et trousses pour le traitement du cancer | |
WO2013114367A8 (fr) | Anticorps de c10rf32 et leurs utilisations pour traiter le cancer | |
WO2012177595A9 (fr) | Compositions et méthodes pour la thérapie et le diagnostic du cancer | |
HK1199100A1 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
MX2011010955A (es) | Terapia complementaria contra el cancer. | |
WO2011130164A3 (fr) | Anticorps anti-tfr non conjugués et compositions de ceux-ci pour le traitement de cancers | |
WO2012006634A3 (fr) | Thérapie peptidique par antigène prostatique spécifique (psa) | |
EP2651443A4 (fr) | Anticorps anti-ccl25 et anti-ccr9 pour la prévention et le traitement du cancer et de la migration de cellules cancéreuses | |
RS56187B1 (sr) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
EP2590712A4 (fr) | Système et procédé pour un traitement hyperthermique de tumeur | |
WO2011153243A3 (fr) | Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac | |
EP2635273A4 (fr) | Compositions d'isoflavonoïdes et méthodes de traitement du cancer | |
EP2547368A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
WO2011133480A3 (fr) | Procédé de traitement du cancer gastrique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11726014 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11726014 Country of ref document: EP Kind code of ref document: A2 |